Us Bancorp \De\ Bio Atla, Inc. Transaction History

Us Bancorp \De\

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 01, 2022	SELL	$2.13 - $5.38 $558 - $1,409	-262 Closed	0 $0
Q1 2022 May 11, 2022	BUY	$4.38 - $18.78 $367 - $1,577	84 Added 47.19%	262 $1,000
Q4 2021 Feb 11, 2022	SELL	$19.0 - $30.95 $3,496 - $5,694	-184 Reduced 50.83%	178 $3,000
Q3 2021 Nov 10, 2021	BUY	$29.44 - $43.74 $9,568 - $14,215	325 Added 878.38%	362 $11,000
Q2 2021 Aug 05, 2021	BUY	$38.07 - $56.17 $1,408 - $2,078	37 New	37 $2,000

24.8M

140K

4.6K

Ticker BCAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,304,100
Market Cap $47.9M
Description
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

Stay updated on Us Bancorp \De\ with notifications on news.